480 related articles for article (PubMed ID: 28154831)
1. Targeting
Fleurence J; Fougeray S; Bahri M; Cochonneau D; Clémenceau B; Paris F; Heczey A; Birklé S
J Immunol Res; 2017; 2017():5604891. PubMed ID: 28154831
[TBL] [Abstract][Full Text] [Related]
2. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.
Ahmed M; Cheung NK
FEBS Lett; 2014 Jan; 588(2):288-97. PubMed ID: 24295643
[TBL] [Abstract][Full Text] [Related]
3. GD2-targeted immunotherapy and radioimmunotherapy.
Dobrenkov K; Cheung NK
Semin Oncol; 2014 Oct; 41(5):589-612. PubMed ID: 25440605
[TBL] [Abstract][Full Text] [Related]
4. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.
Cheung NK; Canete A; Cheung IY; Ye JN; Liu C
Int J Cancer; 1993 May; 54(3):499-505. PubMed ID: 8509225
[TBL] [Abstract][Full Text] [Related]
5. A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies.
Ye JN; Cheung NK
Int J Cancer; 1992 Jan; 50(2):197-201. PubMed ID: 1730513
[TBL] [Abstract][Full Text] [Related]
6. Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside.
Fleurence J; Cochonneau D; Fougeray S; Oliver L; Geraldo F; Terme M; Dorvillius M; Loussouarn D; Vallette F; Paris F; Birklé S
Oncotarget; 2016 Jul; 7(27):41172-41185. PubMed ID: 27172791
[TBL] [Abstract][Full Text] [Related]
7. Structural and immunological characterization of O-acetylated GD2. Evidence that GD2 is an acceptor for ganglioside O-acetyltransferase in human melanoma cells.
Sjoberg ER; Manzi AE; Khoo KH; Dell A; Varki A
J Biol Chem; 1992 Aug; 267(23):16200-11. PubMed ID: 1644805
[TBL] [Abstract][Full Text] [Related]
8. NGcGM3 ganglioside: a privileged target for cancer vaccines.
Fernandez LE; Gabri MR; Guthmann MD; Gomez RE; Gold S; Fainboim L; Gomez DE; Alonso DF
Clin Dev Immunol; 2010; 2010():814397. PubMed ID: 21048926
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Strategies for Human IgM Antibodies Directed at Tumor-Associated Ganglioside Antigens: Discoveries Made During the Morton Era and Future Directions.
Jones PC; Irie RF
Crit Rev Oncog; 2016; 21(1-2):75-81. PubMed ID: 27481004
[TBL] [Abstract][Full Text] [Related]
10. Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo.
Cochonneau D; Terme M; Michaud A; Dorvillius M; Gautier N; Frikeche J; Alvarez-Rueda N; Bougras G; Aubry J; Paris F; Birklé S
Cancer Lett; 2013 Jun; 333(2):194-204. PubMed ID: 23370223
[TBL] [Abstract][Full Text] [Related]
11. Ganglioside antigens expressed by human cancer cells.
Ritter G; Livingston PO
Semin Cancer Biol; 1991 Dec; 2(6):401-9. PubMed ID: 1810468
[TBL] [Abstract][Full Text] [Related]
12. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
Vincent M; Bessard A; Cochonneau D; Teppaz G; Solé V; Maillasson M; Birklé S; Garrigue-Antar L; Quéméner A; Jacques Y
Int J Cancer; 2013 Aug; 133(3):757-65. PubMed ID: 23354868
[TBL] [Abstract][Full Text] [Related]
13. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
14. Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis.
Cheresh DA; Rosenberg J; Mujoo K; Hirschowitz L; Reisfeld RA
Cancer Res; 1986 Oct; 46(10):5112-8. PubMed ID: 3019521
[TBL] [Abstract][Full Text] [Related]
15. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
16. Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside.
Basak S; Birebent B; Purev E; Somasundaram R; Maruyama H; Zaloudik J; Swoboda R; Strittmatter W; Li W; Luckenbach A; Song H; Li J; Sproesser K; Guerry D; Nair S; Furukawa K; Herlyn D
Cancer Immunol Immunother; 2003 Mar; 52(3):145-54. PubMed ID: 12649743
[TBL] [Abstract][Full Text] [Related]
17. Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside.
Fleurence J; Bahri M; Fougeray S; Faraj S; Vermeulen S; Pinault E; Geraldo F; Oliver L; Véziers J; Marquet P; Rabé M; Gratas C; Vallette F; Pecqueur C; Paris F; Birklé S
Int J Cancer; 2020 Jan; 146(2):424-438. PubMed ID: 31241171
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy.
Rashidijahanabad Z; Huang X
Semin Immunol; 2020 Feb; 47():101390. PubMed ID: 31982247
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2.
Sen G; Chakraborty M; Foon KA; Reisfeld RA; Bhattacharya-Chatterjee M
Clin Cancer Res; 1997 Nov; 3(11):1969-76. PubMed ID: 9815586
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia.
Terme M; Dorvillius M; Cochonneau D; Chaumette T; Xiao W; Diccianni MB; Barbet J; Yu AL; Paris F; Sorkin LS; Birklé S
PLoS One; 2014; 9(2):e87210. PubMed ID: 24520328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]